You are here: Industry Insights > Amgen

News List

CCRM and Amgen Partner to Advance Emerging Medical Innovations contractpharma
May 06, 2021
New regenerative medicine discoveries, including cell and gene therapies, will never reach patients without access to the funding, expertise and other specialized support that are required to move along the commercialization pathway.
Breakthrough designation granted for Amgen’s bemarituzumab pharmatimes
April 21, 2021
Amgen’s investigational medicine bemarituzumab has received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA).
Amgen Completes Five Prime Acquisition contractpharma
April 19, 2021
Amgen has completed its acquisition of Five Prime Therapeutics for approximately $1.9 billion in cash. This acquisition adds Five Prime's innovative pipeline of immuno-oncology and targeted cancer therapies to Amgen's oncology portfolio.
Healthcare industry reported 119 deals worth $10.8 billion in March 2021 expresspharma
April 08, 2021
In March 2021, the healthcare industry reported 119 deals worth $10.8 billion as compared to the last 12-month average (March 2020 to February 2021) of 94 deals worth $20 billion.
Amgen agrees to acquire biopharmaceutical company Rodeo Therapeutics pharmaceutical-business-review
March 31, 2021
Biotechnology company Amgen has agreed to acquire privately held biopharmaceutical company Rodeo Therapeutics.
NICE recommends Kyprolis triple combination treatment for multiple myeloma pharmatimes
March 22, 2021
The National Institute for Health and Care Excellence (NICE) has recommended a triple combination therapy comprised of Amgen’s Kyprolis, lenalidomide and dexamethasone for the treatment of previously-treated multiple myeloma patients.
QLHC Concludes Apremilast Not Likely to Reduce Time to COVID Recovery, Mortality americanpharmaceuticalreview
March 22, 2021
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility.
Amgen to Acquire Five Prime Therapeutics for $1.9B contractpharma
March 05, 2021
Amgen entered an agreement to acquire Five Prime Therapeutics for approximately $1.9 billion in cash. This acquisition adds Five Prime's innovative pipeline of immuno-oncology and targeted cancer therapies to Amgen's oncology portfolio.
Tezepelumab significantly reduces exacerbations of severe asthma europeanpharmaceuticalreview
March 02, 2021
In a Phase III trial, tezepelumab was shown to meaningfully reduce annualised asthma exacerbation rates in a range of patients with severe, uncontrolled asthma.
Amgen looks to expand access to Otezla in the US pharmatimes
February 24, 2021
Amgen has submitted a supplemental new drug application (sNDA) seeking expanded approval for Otezla in adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page